TriSalus Life Sciences Strengthens Commercial and Operational Leadership, Names Daniel Estay as Its Chief Business Officer

Leadership Appointment Supports Strategic Shift to Build Oncology
Drug Delivery Company

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences announced the appointment of Daniel Estay as its
chief business officer, reporting to the company’s chief executive
officer, Mary Szela. The appointment deepens the leadership capabilities
of the company, supporting its strategic shift to become a leader in
oncology drug delivery. Prior to joining TriSalus Life Sciences, Estay
was consulting for medical technology companies and also served as
co-founder and chief executive officer of SonoVascular Inc., a
pre-clinical stage company focused on advancing the treatment of blood
clots using intrasvascular ultrasound technology.

Throughout his career, Estay has held a variety of executive operational
and commercial roles in health care, with extensive experience in
interventional medical technology. He has established a strong record of
accomplishment, creating leadership positions for products under his
management. In addition to operating and commercial responsibilities,
Estay has held roles in business development where he was responsible
for creating and executing M&A and licensing strategies to build aligned
product portfolios and secure capital for investment. In more than a
decade with Abbott, he held leadership positions in general management
and business development, including 6 years overseeing Abbott’s vascular
device business in Asia Pacific & Japan. Estay received his BS degree in
Business Administration from Syracuse University and an MBA from the
University of Miami.

“Dan brings insight and capabilities with a deep understanding around
how to build value for clinicians and patients, all while delivering
stellar business results. His knowledge of interventional medicine is
extensive and his track record supports his ability to create market
leadership for products and brands on a global scale,” said Szela. “I’m
thrilled to have Dan join TriSalus as a member of my leadership team. I
know he has the capability and shares our collective commitment to
advance the strategic mission of the company as we build our
capabilities in oncology drug delivery.”

“The technology platform at TriSalus is compelling and has the potential
to significantly change the way in which we intervene and treat cancer
by combining immuno-oncology therapies with specialized drug delivery
devices,” said Estay. ”I’m very pleased to be joining the organization
at such an important time and look forward to building the necessary
capabilities to enhance the way we provide care for patients.”

About Pressure-enabled Drug Delivery™ (PEDD)

The high intratumoral pressure created by the tumor microenvironment
limits the flow and accumulation of therapy in solid tumors.
Interventional medical devices employing Pressure-enabled Drug DeliveryTM
(PEDD) can improve drug delivery to the tumor by creating a favorable
pressure gradient that penetrates the hostile tumor microenvironment and
increases drug concentration in the tumor without increasing systemic
toxicity. Locoregional infusion with the Surefire-patented technology
has been used in nearly 8,000 procedures worldwide for liver cancer and
can be applied to a variety of other high-pressure solid tumors.

About TriSalus Life Sciences

TriSalus Life Sciences, previously known as Surefire Medical, is a
privately held medical device firm in Westminster, CO, focused on making
the administration of cancer therapies safer and more effective for
patients. The company created the Pressure-enabled Drug Delivery™ (PEDD)
technology and is committed to developing other applications of the
technology for use in other solid tumors and for the administration of
immuno-oncology (IO) therapies. TriSalus Life Sciences was founded in
2011.

Contacts

Outcomes Communication Group
Laureen Cassidy
laureen@outcomescg.com

Sky Optics Media drone video